GlassScriptPhysician profile
Brian T Burry
NPI 1578675773
$2,222.88
in general payments reported to CMS, 2019-2025
21 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $118 · 2021: $323 · 2022: $519 · 2023: $269 · 2024: $424 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.75 | 2022-2025 | Durysta, Vuity, Lumigan |
| Alcon Vision LLC | $268.17 | 2019-2025 | Clareon, Rocklatan |
| Sun Pharmaceutical Industries INC. | $199.40 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $155.86 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $129.84 | 2022-2025 | Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $113.74 | 2019-2022 | |
| Dompe US, INC. | $109.90 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $99.88 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $69.41 | 2020-2024 | Veritas Vision System |
| Glaukos Corporation | $67.92 | 2021-2024 | Idose |
| Aerie Pharmaceuticals, INC. | $55.91 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $49.17 | 2020-2021 | |
| Harrow Eye, LLC | $43.93 | 2024 | Vevye |
| Shire North American Group INC | $38.92 | 2019 | |
| Rayner Intraocular Lenses Limited | $38.29 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.93 | 2021 | |
| Thea Pharma INC. | $25.92 | 2025 | Iyuzeh |
| Coopervision INC. | $19.98 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.88 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $14.41 | 2021 | |
| Biotissue Holdings INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Burry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.